Literature DB >> 1985758

Osteosarcoma in young children.

H Kozakewich1, A R Perez-Atayde, A M Goorin, R H Wilkinson, M C Gebhardt, G F Vawter.   

Abstract

The clinicopathologic features of osteosarcoma in 12 children younger than 16 years of age treated at The Children's Hospital and Dana-Farber Cancer Institute, Boston, during a 70-year time period are presented. Only one of six children treated before 1972 is a long-term survivor. Four of six children (67%) treated after 1972 are disease-free with an average follow-up of 8.8 years. The year 1972 marked the onset of use of effective chemotherapy in osteosarcoma, namely, high-dose methotrexate and leucovorin rescue. It would appear that the pathologic features and behavior of osteosarcoma in young children is similar to that of osteosarcoma in older children and adolescents. A combination of complete (wide) surgical resection or amputation and aggressive chemotherapy offers the best chance of long-term survival.

Entities:  

Mesh:

Year:  1991        PMID: 1985758     DOI: 10.1002/1097-0142(19910201)67:3<638::aid-cncr2820670319>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Osteosarcoma in children 5 years of age or younger at initial diagnosis.

Authors:  Jennifer Worch; Katherine K Matthay; John Neuhaus; Robert Goldsby; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

2.  The survival of osteosarcoma patients 10 years old or younger is not worse than the survival of older patients: a retrospective analysis.

Authors:  Jun Ah Lee; Dong Ho Kim; Jung Sub Lim; Kyung Duk Park; Won Seok Song; Soo-Yong Lee; Dae-Geun Jeon
Journal:  Cancer Res Treat       Date:  2007-12-31       Impact factor: 4.679

3.  Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases.

Authors:  Maud A M Guillon; Pierre M J Mary; Laurence Brugière; Perrine Marec-Bérard; Hélène D Pacquement; Claudine Schmitt; Jean-Marc Guinebretière; Marie-Dominique P Tabone
Journal:  BMC Cancer       Date:  2011-09-24       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.